Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. has announced a plan to repurchase a portion of its A shares, with the aim of implementing an employee equity incentive scheme. The repurchase, valued between RMB20 million and RMB40 million, is intended to align the interests of shareholders, the company, and its employees, thereby enhancing investor confidence. This strategic move is expected to establish a long-term incentive mechanism, although the actual repurchase will depend on market conditions.
The most recent analyst rating on (HK:9995) stock is a Sell with a HK$75.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative biologics, with a market emphasis on creating therapeutic solutions for oncology and autoimmune diseases.
Average Trading Volume: 5,736,946
Technical Sentiment Signal: Buy
Current Market Cap: HK$50.06B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.